GSK933776
2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
2
Ongoing
0
Recruiting
0
Completed
2
Sites
12
Countries
3
Endpoints
7
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 7 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 1 of 7 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT00459550A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease | GSK933776 Alzheimer’s disease | Alzheimer's disease | Ph 1 | Completed | 7 | May 2011 | 1 | |
| NCT01424436Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient | GSK933776 Alzheimer’s disease, MCI / preclinical Alzheimer’s | MMSE 20-26 | Ph 1 | Completed | 7 | Dec 2011 | 2 |
Showing 1-2 of 2 trials